NAM protects against cisplatin-induced acute kidney injury by suppressing the PARP1/p53 pathway

Wenwen Wu, Ying Fu, Zhiwen Liu, Shaoqun Shu, Ying Wang, Chengyuan Tang, Juan Cai, Zheng Dong

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Cisplatin is a commonly used anti-cancer drug, but it induces nephrotoxicity. As a water-soluble vitamin B family member, nicotinamide (NAM) was recently demonstrated to have beneficial effects for renal injury, but its underlying mechanism remains largely unclear. Here, we suggest that NAM may exert protective effects against cisplatin-induced acute kidney injury (AKI) mainly via suppressing the poly ADP-ribose polymerase 1 (PARP1)/p53 pathway. In our experiment, NAM protected against cisplatin-induced apoptosis both in cultured renal proximal tubular cells and AKI in mice. Mechanistically, NAM suppressed the expression and activation of p53, a known mediator of cisplatin-induced AKI. Upstream of p53, NAM attenuated the induction of γ-H2AX, a hallmark of DNA damage response. Interestingly, PARP1 was activated in cisplatin AKI and this activation was inhibited by NAM. Pharmacological inhibition of PARP1 with PJ34 significantly ameliorated p53 activation and cisplatin-induced cell death in RPTCs and AKI in mice. Thus, NAM may protect against cisplatin-induced AKI by suppressing the PARP1/p53 pathway.

Original languageEnglish (US)
Article number115492
JournalToxicology and Applied Pharmacology
StatePublished - May 1 2021


  • Acute Kidney Injury
  • Cisplatin
  • Nicotinamide
  • PARP1
  • p53

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'NAM protects against cisplatin-induced acute kidney injury by suppressing the PARP1/p53 pathway'. Together they form a unique fingerprint.

Cite this